CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CING CINGULATE INC.

Pre-Mkt 04-22 05:23:59 EDT

5.86

-0.17

-2.82%

盘前6.13

+0.27+4.61%

04:06 EDT

High6.60	Low5.85	Vol733.63K
Open6.12	D1 Closing6.03	Amplitude12.52%
Mkt Cap71.79M	Tradable Cap69.82M	Total Shares12.25M
T/O4.51M	T/O Rate6.16%	Tradable Shares11.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CING","market":"US","secType":"STK","nameCN":"CINGULATE INC.","latestPrice":5.86,"timestamp":1776801600000,"preClose":6.03,"halted":0,"volume":733630,"hourTrading":{"tag":"盘前","latestPrice":6.13,"preClose":5.86,"latestTime":"04:06 EDT","volume":265,"amount":1610.569936,"timestamp":1776845190447,"change":0.27,"changeRate":0.046075,"amplitude":0.011945},"delay":0,"changeRate":-0.02819237147595355,"floatShares":11914000,"shares":12250600,"eps":-4.44084,"marketStatus":"Pre-Mkt","change":-0.17,"latestTime":"04-22 05:23:59 EDT","open":6.12,"high":6.6,"low":5.845,"amount":4513448.4633679995,"amplitude":0.125207,"askPrice":6.93,"askSize":100,"bidPrice":5.83,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.44084,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776864600000},"marketStatusCode":1,"adr":0,"listingDate":1633579200000,"exchange":"NASDAQ","adjPreClose":5.86,"preHourTrading":{"tag":"盘前","latestPrice":6.13,"preClose":5.86,"latestTime":"04:06 EDT","volume":265,"amount":1610.569936,"timestamp":1776845190447,"change":0.27,"changeRate":0.046075,"amplitude":0.011945},"postHourTrading":{"tag":"盘后","latestPrice":6.05,"preClose":5.86,"latestTime":"19:52 EDT","volume":13959,"amount":82876.9558,"timestamp":1776815545985,"change":0.19,"changeRate":0.032423,"amplitude":0.046075},"volumeRatio":1.7135870192025957},"requestUrl":"/m/hq/s/CING/wiki","defaultTab":"wiki","newsList":[{"id":"2627773422","title":"Cingulate files to sell 4.21M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2627773422","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627773422?lang=en_us&edition=fundamental","pubTime":"2026-04-15 05:30","pubTimestamp":1776202217,"startTime":"0","endTime":"0","summary":"17:27 EDT Cingulate (CING) files to sell 4.21M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, ma...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-files-to-sell-4-21m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-files-to-sell-4-21m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CING"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625917087","title":"Cingulate Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2625917087","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625917087?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:09","pubTimestamp":1775642940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CING/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 06:09 ET (10:09 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CING"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624871346","title":"Cingulate Adds Independent Director Jiang to Board Committees","url":"https://stock-news.laohu8.com/highlight/detail?id=2624871346","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624871346?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:51","pubTimestamp":1775163111,"startTime":"0","endTime":"0","summary":"Cingulate Inc ( ($CING) ) has shared an update. On March 27, 2026, Cingulate Inc. appointed Zhanpeng “Frederick” Jiang to its Board of Directors as...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cingulate-adds-independent-director-jiang-to-board-committees?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cingulate-adds-independent-director-jiang-to-board-committees?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624823666","title":"Cingulate appoints Zhanpeng “Frederick” Jiang to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2624823666","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624823666?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:11","pubTimestamp":1775160663,"startTime":"0","endTime":"0","summary":"Cingulate appointed Zhanpeng “Frederick” Jiang to board of directors on March 27, 2026, effective immediately.Jiang will serve as Class I director through 2028 annual meeting of stockholders.Jiang also joined Nominating and Corporate Governance Committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3mfsZj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622401627","title":"Cingulate Announces ATM Equity Program and Share Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2622401627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622401627?lang=en_us&edition=fundamental","pubTime":"2026-03-25 05:54","pubTimestamp":1774389258,"startTime":"0","endTime":"0","summary":"Cingulate Inc ( ($CING) ) has issued an announcement. On March 24, 2026, Cingulate Inc. entered into an at-the-market sales agreement with A.G.P./A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cingulate-announces-atm-equity-program-and-share-issuance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cingulate-announces-atm-equity-program-and-share-issuance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","BK4585","BK4215","EQR","CING"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622015073","title":"Cingulate Inc: Files Prospectus Supplement Relates to Issuance and Sale of Common Stock of up to $100 Mln From Time to Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2622015073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622015073?lang=en_us&edition=fundamental","pubTime":"2026-03-25 05:20","pubTimestamp":1774387224,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C163:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CING"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622015753","title":"Cingulate held special stockholder meeting to approve issuance proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2622015753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622015753?lang=en_us&edition=fundamental","pubTime":"2026-03-25 05:15","pubTimestamp":1774386927,"startTime":"0","endTime":"0","summary":"Cingulate held a special meeting of stockholders on March 24, 2026.Approval was also given to adjourn the special meeting to a later date if needed to solicit additional proxies for the issuance matter, though the adjournment was not required.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL1NHmtv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CING"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621083499","title":"Cingulate Is Maintained at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2621083499","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621083499?lang=en_us&edition=fundamental","pubTime":"2026-03-24 01:36","pubTimestamp":1774287360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CING/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 13:36 ET (17:36 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CING"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621744935","title":"Cingulate price target lowered to $14 from $16 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2621744935","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621744935?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:30","pubTimestamp":1774218608,"startTime":"0","endTime":"0","summary":"Roth Capital lowered the firm’s price target on Cingulate (CING) to $14 from $16 and keeps a Buy rating on the shares. The company’s new drug appli...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-price-target-lowered-to-14-from-16-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-price-target-lowered-to-14-from-16-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CING"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621875578","title":"Analysts Offer Insights on Healthcare Companies: 20/20 Biolabs, Inc. (AIDX) and Cingulate Inc (CING)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621875578","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621875578?lang=en_us&edition=fundamental","pubTime":"2026-03-21 02:10","pubTimestamp":1774030246,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on 20/20 Biolabs, Inc. (AIDX) and Cingulate Inc (CING) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-20-20-biolabs-inc-aidx-and-cingulate-inc-cing-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-20-20-biolabs-inc-aidx-and-cingulate-inc-cing-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","XLV","CING","BK4007","HCSG","BK4137","AIDX","BK4588","LU0128526141.USD","BK4581","LABU","XBI","LU0029874061.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620189733","title":"Cingulate files to sell 3.5M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2620189733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620189733?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:46","pubTimestamp":1774007169,"startTime":"0","endTime":"0","summary":"07:40 EDT Cingulate (CING) files to sell 3.5M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-files-to-sell-3-5m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-files-to-sell-3-5m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782541","title":"Cingulate Inc - Files to Offer and Resale of up to 3.5 Mln Shares by Lincoln Park Capital Fund - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620782541?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:03","pubTimestamp":1774001002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN40806G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CING"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620263988","title":"Cingulate Tumbles on Wider-Than-Expected 4Q Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2620263988","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620263988?lang=en_us&edition=fundamental","pubTime":"2026-03-19 00:56","pubTimestamp":1773852960,"startTime":"0","endTime":"0","summary":"Shares of Cingulate fell after the biopharmaceutical company posted a wider-than-expected loss in the fourth quarter.The stock was down 27%, at $8.55, midday Wednesday, but has more than doubled in value over the past year.The company on Wednesday reported a loss of $6.3 million, compared with a loss of $6.2 million a year earlier.The Kansas City, Kan., company's full-year loss came out to $22.4 million, wider than its 2024 loss of $16.6 million.Analysts were expecting a fourth-quarter loss of $4.8 million and a full-year loss of $20.8 million.The company received a notice of allowance for its U.S. patent application for CTx-1301 on Tuesday. The patent, upon issuance, would protect key elements of the drug's formulation and method of use through May 2042, the company said.Cingulate said Wednesday that its cash on hand would support its capital needs late into the fourth quarter as it seeks approval for and prepares to commercialize CTx-1301. It ended 2025 with about $11 million in cash","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620255083","title":"Cingulate Q4 EPS $(0.84) Misses $(0.61) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620255083","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620255083?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:47","pubTimestamp":1773838076,"startTime":"0","endTime":"0","summary":"Cingulate (NASDAQ:CING) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.61) by 37.03 percent. This is a 500 percent decrease over losses of $(0.14) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51322404/cingulate-q4-eps-0-84-misses-0-61-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253957","title":"ADHD drug developer Cingulate's Q4 net loss misses analyst expectations as G&A costs rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253957","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253957?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:10","pubTimestamp":1773835855,"startTime":"0","endTime":"0","summary":"ADHD drug developer Cingulate's Q4 net loss misses analyst expectations as G&A costs riseOverviewUS biopharma firm's Q4 net loss widened and missed analyst expectationsR&D expenses fell while G&A cost","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL1N4060HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253356","title":"Cingulate Q4 net loss was USD 6.27 million as G&A expenses rose 91% to USD 3.58 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253356","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253356?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:04","pubTimestamp":1773835493,"startTime":"0","endTime":"0","summary":"Cingulate published a fourth-quarter and full-year 2025 earnings release, reporting a Q4 net loss of USD 6.27 million and a FY net loss of USD 22.45 million. FY general and administrative expense rose 64% to USD 10.16 million, driven by higher pre-commercialization costs, personnel expenses and legal and professional fees. As of Dec. 31, cash and cash equivalents were USD 10.95 million and working capital was USD 1.7 million. The company said current cash on hand is expected to fund operations into late Q4 2026 under its current plan focused on regulatory approval and pre-commercialization for CTx-1301. Management said the FDA accepted the CTx-1301 NDA under the 505 pathway with a PDUFA target action date of May 31, 2026, and that recent FDA information requests relate to manufacturing and CMC rather than clinical safety or efficacy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7gTTdV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","BK4585","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","BK4007","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","CING","LU0314104364.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620042258","title":"Cingulate Q4 Net Income USD -6.3 Million VS. Ibes Estimate USD -4.52 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620042258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620042258?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:00","pubTimestamp":1773835201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nPLXFC1B7C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CING"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620846253","title":"Press Release: Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2620846253","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620846253?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:00","pubTimestamp":1773835200,"startTime":"0","endTime":"0","summary":"KANSAS CITY, Kan., March 18, 2026  -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release  drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application  for its lead candidate, CTx-1301 .Cingulate received a European patent for CTx-1301 covering the specificity of its tri-modal, precision-timed pulsatile release profile for the treatment of ADHD. The patent , granted on December 17, 2025, extends protection through May 2042 and is expected to be validated in more than 30 European territories, including the United Kingdom.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4007","TM","BK4585","PIPE","BK4139","BK4099","BK4588","CING","BK4555","BK4604","ABVC","ADHD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620311922","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2620311922","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620311922?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:00","pubTimestamp":1773828000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Accenture Plc A                                  2Q      2.85   6:39 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLY","GUTS","CLLS","ABVX","DRIO","GANX","GEMI","GIS","FUFU","CCL","ARCO","ABSI","ARX","CURV","CNM","BRAG","AEBI","MXCT","ETON","AVAH","CRIS","ECOR","ALVO","DRI","FBRX","BIOA","BRZE","EQPT","FIVE","AIR","CUK","BABA","BGSI","FDX","BZ","CDNL","DLO","ELDN","ACN","CELC","CNXC","GRWG","HNRG","CAL","DERM","EVTL","CING","BZAI","AVR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2617545487","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2617545487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617545487?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:00","pubTimestamp":1772708400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CPI Card Grp                                    4Q       .65   7:00 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BVS","AMTX","ASMB","CHRS","ALNT","CANG","CTOS","BNTX","BJ","BODI","AEYE","ARQ","ANNX","COO","ACCO","COOK","BCIC","CLYM","COST","FCEL","ALGS","ALT","BURL","CING","AMBQ","BLND","OLPX","ADCT","AMPX","ACET","CRVS","AKA","CRMD","BTAI","CGEM","CLAR","CASY","CNQ","CTNM","AQN","ABM","APYX","BBCP","CIEN","BETA","ATHM","CCEC","BRLT"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.cingulate.com","stockEarnings":[{"period":"1week","weight":0.0953},{"period":"1month","weight":-0.206},{"period":"3month","weight":0.0597},{"period":"6month","weight":0.6369},{"period":"1year","weight":0.4398},{"period":"ytd","weight":0.3502}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0856},{"period":"3month","weight":0.0273},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.3701},{"period":"ytd","weight":0.0325}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.143656},{"month":2,"riseRate":0.4,"avgChangeRate":0.01358},{"month":3,"riseRate":0.4,"avgChangeRate":-0.044027},{"month":4,"riseRate":0.2,"avgChangeRate":-0.064947},{"month":5,"riseRate":0,"avgChangeRate":-0.197282},{"month":6,"riseRate":0.75,"avgChangeRate":-0.035954},{"month":7,"riseRate":0.5,"avgChangeRate":-0.055289},{"month":8,"riseRate":0.75,"avgChangeRate":0.301563},{"month":9,"riseRate":0.25,"avgChangeRate":-0.156522},{"month":10,"riseRate":0.25,"avgChangeRate":-0.153936},{"month":11,"riseRate":0.25,"avgChangeRate":-0.072096},{"month":12,"riseRate":1,"avgChangeRate":0.130431}],"exchange":"NASDAQ","name":"CINGULATE INC.","nameEN":"CINGULATE INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CINGULATE INC.(CING) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CINGULATE INC.,CING,CINGULATE INC.股票,CINGULATE INC.股票老虎,CINGULATE INC.股票老虎国际,CINGULATE INC.行情,CINGULATE INC.股票行情,CINGULATE INC.股价,CINGULATE INC.股市,CINGULATE INC.股票价格,CINGULATE INC.股票交易,CINGULATE INC.股票购买,CINGULATE INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CINGULATE INC.(CING) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction